A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2002
10/10/2002	WO2001072685A9 Polyamine analogues as cytotoxic agents
10/10/2002	WO2001053324A8 Novel haptotactic peptides
10/10/2002	US20020147999 Reducing neuronal tangles in alzhemier's patients; obtain human, administer modulator, monitor development of neuronal tangles in, reduction in neuronal tangles indicates modulator
10/10/2002	US20020147997 Animal model for use in the diagnosis, prevention and treatment of cancer
10/10/2002	US20020147305 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
10/10/2002	US20020147213 Side effect reduction; synergistic mixture
10/10/2002	US20020147206 Synergistic mixture of neurotransmitter and antidepressant
10/10/2002	US20020147203 Tyrosine kinase inhibitors
10/10/2002	US20020147197 Methods and compositions for enhancing pharmaceutical treatments
10/10/2002	US20020147189 Immunology response; autoimmune disease
10/10/2002	US20020147184 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
10/10/2002	US20020147162 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (PTTG)
10/10/2002	US20020147161 Novel antisense inhibition of rad51
10/10/2002	US20020147160 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
10/10/2002	US20020147158 Composition and method for preventing and treating sinusoidal obstruction syndrome and radiation-induced liver disease
10/10/2002	US20020147157 Combination therapy comprising anti-diabetic and anticonvulsant agents
10/10/2002	US20020147143 Diagnosis, therapy; anticancer agents
10/10/2002	US20020147139 Viricides
10/10/2002	US20020147138 Anticancer agents
10/10/2002	US20020147131 Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused skeletal muscle tissue
10/10/2002	US20020147130 Treatment of hiv
10/10/2002	US20020147129 Polypeptides; nervous system, brain disorders
10/10/2002	US20020146805 DNA encoding the human serine protease T
10/10/2002	US20020146797 Genetically engineered enzyme for use in the treatment of cell proliferative disorders
10/10/2002	US20020146792 Nucleotide sequences coding protein for use in the treatment of atherosclerosis
10/10/2002	US20020146774 Smad2 phosphorylation and interaction with Smad4
10/10/2002	US20020146773 ''Signalin'' family of TGFbeta signal transduction proteins, and uses related thereto
10/10/2002	US20020146770 RAS proteins
10/10/2002	US20020146760 G protein-coupled receptor for use in treatment of alzheimer's disease
10/10/2002	US20020146759 Stress proteins and peptides and methods of use thereof
10/10/2002	US20020146749 Diagnosis and treatment of neuroectodermal tumors
10/10/2002	US20020146474 For prophylaxis and therapy of cellulite and localized dermal excess adipose, for treating obesity
10/10/2002	US20020146469 Administering a sensory regimen which reduces or down-regulates the activity of the hypothalamus-pituitary-adrenal (HPA) axis
10/10/2002	US20020146468 Therapy and prophylaxis of diabetes by administering to a human or animal an effective dosage of an extract of plant of the genus Trichocaulon or of the genus Hoodia
10/10/2002	US20020146464 Mixing a chloride hydrargyrum material and a gypsum material and pork into particles, and frying particles into pills
10/10/2002	US20020146463 Useful as food additives or in medicaments
10/10/2002	US20020146462 Anti-tumor therapies comprising a combination of a cartilage extract and an anti-neoplastic agent providing high efficacy and low toxic side effects
10/10/2002	US20020146450 Liposome-entrapped topoisomerase inhibitors
10/10/2002	US20020146440 Reduces the healing and recovery time of skin that has been damaged
10/10/2002	US20020146426 Administering molecule joined to a heat shock protein or molecule joined to an adenosinetriphosphate (ATP) binding domain of a heat shock protein inducing an immune response that includes a CD8+ cytotoxic T lymphocyte (CTL) response
10/10/2002	US20020146421 Diagnosis and treatment of malignant neoplasms
10/10/2002	US20020146397 Unblocking immunization at a regional lymph node by: promoting differentiation and maturation of immature dendritic cells in a regional lymph node and; allowing presentation by resulting mature dendritic cells of antigen to T-cells
10/10/2002	US20020146374 For therapy of candidiasis
10/10/2002	DE10116768A1 Hypoglycemic medicaments useful for treating type II diabetes contain new or known N-aroyl-N'-phenyl-urea derivatives which are glycogen phosphorylase a inhibitors
10/10/2002	DE10115073A1 Verwendung von Inhibitoren von IKK-ß und Verfahren zum Auffinden solcher Inhibitoren Use of inhibitors of IKK-ß and methods for finding such inhibitors
10/10/2002	CA2455915A1 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
10/10/2002	CA2443355A1 Central nervous system neural progenitor cell which induces synapse-forming neurons in the spinal cord
10/10/2002	CA2443050A1 Immunomodulation and effect on cell processes relating to serotonin family receptors
10/10/2002	CA2442801A1 Recombinant antibodies coexpressed with gntiii
10/10/2002	CA2442674A1 Phosphoprotein target for insulin and its antagonists
10/10/2002	CA2442531A1 Peptides and antibodies to muc 1 proteins
10/10/2002	CA2442525A1 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
10/10/2002	CA2442484A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
10/10/2002	CA2442457A1 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
10/10/2002	CA2442455A1 A method of treating proliferative diseases using eg5 inhibitors
10/10/2002	CA2442452A1 Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
10/10/2002	CA2442437A1 Agent for the treatment of overactive bladder
10/10/2002	CA2442428A1 Novel tyrosine kinase inhibitors
10/10/2002	CA2442410A1 Duloxetine for treatment of hot flashes
10/10/2002	CA2442363A1 Reducing the immunogenicity of fusion proteins
10/10/2002	CA2442330A1 Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
10/10/2002	CA2442328A1 Therapeutic combinations for cardiovascular and inflammatory indications
10/10/2002	CA2442064A1 G-protein coupled receptors
10/10/2002	CA2442062A1 Secreted proteins
10/10/2002	CA2441970A1 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
10/10/2002	CA2441654A1 Cytoskeleton-associated proteins
10/10/2002	CA2441562A1 Short bioactive peptides and methods for their use
10/10/2002	CA2441335A1 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
10/10/2002	CA2440831A1 Combination therapy using cd40 and cd20 ligands
10/10/2002	CA2440534A1 Antitumor methods and compositions comprising sesquiterpene derivatives
10/10/2002	CA2440108A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/10/2002	CA2437789A1 Topical composition comprising an antifungal
10/10/2002	CA2437113A1 N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
10/10/2002	CA2433910A1 Antibiotics from bacteria isolated from amphibian skin
10/09/2002	EP1247860A1 Crystal structure of pyruvate dehydrogenase kinase 2 (PDHK-2) and use thereof in methods for identifying and designing new ligands
10/09/2002	EP1247809A2 Triazine compounds useful as sorbitol dehydrogenase inhibitors
10/09/2002	EP1247533A2 Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
10/09/2002	EP1247532A1 Composition promoting lacrimal secretion
10/09/2002	EP1247524A1 Composition comprising taurolidine and/or taurultam for the treatment of cancer
10/09/2002	EP1247103A2 Tethered ligands and methods of use
10/09/2002	EP1246946A2 Compositions and methods for the discovery and selection of biological information
10/09/2002	EP1246940A2 Chemotherapeutant screening method
10/09/2002	EP1246923A2 Dna modification proteins
10/09/2002	EP1246918A2 Secreted proteins
10/09/2002	EP1246917A2 Human stra6 polypeptides
10/09/2002	EP1246847A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
10/09/2002	EP1246844A1 Interleukin-1 receptor antagonist-related molecules and uses thereof
10/09/2002	EP1246841A1 Transcription factors containing two potential dna binding motifs
10/09/2002	EP1246838A1 Lipopeptides as antibacterial agents
10/09/2002	EP1246823A1 Pyrimidine and triazine kinase inhibitors
10/09/2002	EP1246818A1 Novel indole derivatives
10/09/2002	EP1246805A1 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
10/09/2002	EP1246789A1 Racemic and optically pure metabolites of sibutramine, their preparation, compositions comprising them and their use as dopamine reuptake inhibitors
10/09/2002	EP1246692A1 Templating of solid particles by polymer multilayers
10/09/2002	EP1246639A2 Glp-2 formulations
10/09/2002	EP1246634A1 Methods for treating pancreatic disorders
10/09/2002	EP1246632A1 Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses
10/09/2002	EP1246631A1 Method and device for increasing and/or decreasing the concentration of immunomodulatory-active substances in substance mixtures
10/09/2002	EP1246630A1 Compositions and methods for facilitating skin growth and managing skin conditions
10/09/2002	EP1246629A1 Methods of using electron active compounds for managing cancer

1 ... 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 ... 1151